Novo Nordisk shares surge on positive early US prescription data for Wegovy pill
Novo Nordisk shares rose over five percent on Friday following positive early US prescription data. This rally comes as the new Wegovy pill begins to reach patients.
Insights:
Novo Nordisk A/S saw its shares climb more than 5% on Friday, January 16, 2026, reaching price levels last touched in October 2025. The market rally follows the release of encouraging early prescription data for the oral version of its weight-loss medication, Wegovy, in the US 
US. The Wegovy pill first became available to patients on January 5, 2026, after receiving approval from the U.S. Food and Drug Administration in December 2025.
US. The Wegovy pill first became available to patients on January 5, 2026, after receiving approval from the U.S. Food and Drug Administration in December 2025.Analysts have pointed to initial script numbers as the primary driver for the stock movement. Sydbank analyst Soren Lontoft Hansen soren lontoft hansenattributed the share rise directly to these encouraging early scripts for the Wegovy pill. Similarly, Nordnet analyst Per Hansen per hansenstated that the increase was likely due to the USscripts data, which investors are monitoring closely as a key metric for success in the intensely competitive weight-loss drug market.
